NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) combined with ICS / LABA treatment of severe asthma can significantly improve lung function

The results of the study show that tiotropium bromide(136310-93-5) inhalation (Respimat) is administered once daily to patients with asthma symptoms after treatment with high doses of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA) , Can significantly improve lung function and reduce acute asthma attacks. The results are also published online in the New England Journal of Medicine.

The two studies of the UniTinA-asthma ™ program were double-blind, parallel-group trials of patients receiving at least a high dose of ICS / LABA, and FEV1 after bronchodilator treatment as a percentage of predicted < 80%, while asthma control questionnaire score ≥ 1.5. A total of 912 patients were routinely treated with tiotropium bromide(136310-93-5) 5ug or placebo for 48 weeks on a routine basis.

Predictors of composite major pulmonary function endpoints included FEV1 peak and trough values at Week 24. Tiotropium bromide(136310-93-5) was associated with a significant improvement in lung function at week 24 (mean ± change in mean FEV1 vs trough vs baseline for tiotropium vs placebo: FEV1 peak FEV1 trough test 1 = 88 ± 34 ml, test 2 = 111 ± 30 ml, p all <0.001)), the effect lasted Up to 48 weeks.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved